FENNEC PHARMACEUTICALS INC. FENC Income Statement

Fennec pharmaceuticals inc. (FENC)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenue
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating expenses:
Research and development
1,393	1,172	795	1,969	1,671	1,723	1,798	798	689	886	492	333	225	174	112	139	47	71	88	54	43	-	88	72	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development Sodium Thiosulfate
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24	89	-224	554	178	562	357	860	296	506	439	234	315	110	146
Impairment of capital assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	-	-
Gain on deferred lease inducements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	-	-
Research and development Eniluracil
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	-	0	0	0	0	0	0	0	0	0	0	0	-	-
General and administrative
2,442	2,481	1,068	2,844	1,009	1,382	1,050	1,867	1,102	1,629	1,694	1,146	546	972	452	568	407	480	250	495	409	626	531	858	505	327	275	373	359	562	273	390	320	395	505	338	706	807	2,359
Total operating expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	630	1,250	-	-	944	572	-	917	2,505
Loss from operations
-3,835	-3,653	-1,863	-4,813	-2,680	-3,105	-2,848	-2,665	-1,791	-2,515	-2,186	-1,479	-771	-1,146	-564	-707	-454	-551	-338	-549	-452	-791	-619	-930	-537	-416	-51	-927	-537	-1,124	-630	-1,250	-616	-901	-944	-572	-1,021	-917	-2,505
Other (expense) income :
Sale of Eniluracil (Note 8)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	40	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized/realized gain on derivatives
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,680	-	-
Other (loss)
-9	-8	1	-10	0	6	-2	5	-3	-4	1	-4	-1	-2	0	-3	-9	-	-2	-10	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-
Unrealized gain/(loss) on derivatives (Note 5)
-	-	0	0	-	0	0	0	167	206	-183	-120	-37	3	19	-17	43	11	216	385	625	2,210	619	181	-2,655	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization expense
17	-	17	-	12	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense
-	-	-	17	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Settlement of Cadherin litigation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	-	-
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	-	-
Gain on derivative settlement (Note 5)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	379	-	-	-2,254	-1,708	7,535	-3,573	-5,396	-139	645	3,327	-	-2,221	225	-	2,570	-72
Other (loss)/gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-7	2	0	-1	0	0	-4	-	0	0	-	28	-
Gain on derivative settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Interest income and other
35	69	70	110	66	115	101	73	59	23	16	5	3	2	3	3	0	-	1	1	-	1	0	3	-2	3	0	-3	2	9	5	3	8	13	21	-1	10	13	8
(Loss)/gain on currency exchange and other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income, net
9	43	54	83	54	121	99	78	223	225	-166	-119	-35	3	62	-17	34	11	215	376	629	2,179	999	180	-2,657	1,528	-1,715	7,534	-3,571	-5,388	-134	648	3,331	4,409	-2,200	224	5,690	2,611	-64
Net loss
-3,826	-3,610	-1,809	-4,730	-2,626	-2,984	-2,749	-2,587	-1,568	-2,290	-2,352	-1,598	-806	-1,143	-502	-724	-420	-540	-123	-173	177	1,388	380	-750	-3,194	1,112	-1,766	6,607	-4,108	-6,512	-764	-602	2,715	3,508	-3,144	-348	4,669	1,694	-2,569
Loss per common share, basic and diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.06	-0.04	-	-	-	-	-	-	-	-	-	-0.21	0.26	-0.16	-	-0.03	-0.02	0.11	-	-0.17	-0.01	-	0.08	-0.01
Basic net loss per common share
0.19	-	-0.09	-0.24	0.14	-	-0.14	-0.14	-0.09	-	-0.15	-0.11	-0.06	-	-0.04	-0.06	-0.04	-	-0.01	-0.02	0.02	-	0.04	-0.08	-0.33	-	-	-	-	-	-	-	-	-	-	-	0.23	-	-
Diluted net loss per common share
0.19	-	-0.09	-0.24	0.14	-	-0.14	-0.14	-0.09	-	-0.15	-0.11	-0.06	-	-0.04	-0.06	-0.04	-	-0.01	-0.02	0.01	-	0.03	-0.08	-0.33	-	-	-	-	-	-	-	-	-	-	-	0.19	-	-
Weighted-average number of common shares outstanding, basic
19,896	19,896	19,896	19,896	19,896	19,785	18,968	18,585	18,430	16,481	15,740	14,192	13,643	-	13,643	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted-average number of common shares outstanding, basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,813	10,942	10,944	10,929	10,830	10,605	-	9,861	9,846	9,769	-19,826	8,386	25,158	25,158	75,423	25,158	25	25	-63,712	18,085	25,158	20,565	20,461	368,294
Weighted-average number of common shares outstanding, diluted
19,896	-	19,896	19,896	19,896	-	18,968	18,585	18,430	-	15,740	14,192	13,643	-	13,643	12,813	10,942	9,679	10,929	10,830	11,870	-	11,154	9,846	9,769	-16,899	8,386	25,639	25,158	75,423	25,158	25	25	-68,147	18,085	25,158	25,001	20,461	368,294